FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4307657319> ?p ?o ?g. }

• W4307657319 endingPage "355" @default.
• W4307657319 startingPage "343" @default.
• W4307657319 abstract "Despite recent approvals, the response to treatment and prognosis of patients with advanced hepatocellular carcinoma (HCC) remain poor. Claudin-1 (CLDN1) is a membrane protein that is expressed at tight junctions, but it can also be exposed non-junctionally, such as on the basolateral membrane of the human hepatocyte. While CLDN1 within tight junctions is well characterized, the role of non-junctional CLDN1 and its role as a therapeutic target in HCC remains unexplored.Using humanized monoclonal antibodies (mAbs) specifically targeting the extracellular loop of human non-junctional CLDN1 and a large series of patient-derived cell-based and animal model systems we aimed to investigate the role of CLDN1 as a therapeutic target for HCC.Targeting non-junctional CLDN1 markedly suppressed tumor growth and invasion in cell line-based models of HCC and patient-derived 3D ex vivo models. Moreover, the robust effect on tumor growth was confirmed in vivo in a large series of cell line-derived xenograft and patient-derived xenograft mouse models. Mechanistic studies, including single-cell RNA sequencing of multicellular patient HCC tumorspheres, suggested that CLDN1 regulates tumor stemness, metabolism, oncogenic signaling and perturbs the tumor immune microenvironment.Our results provide the rationale for targeting CLDN1 in HCC and pave the way for the clinical development of CLDN1-specific mAbs for the treatment of advanced HCC.Hepatocellular carcinoma (HCC) is associated with high mortality and unsatisfactory treatment options. Herein, we identified the cell surface protein Claudin-1 as a treatment target for advanced HCC. Monoclonal antibodies targeting Claudin-1 inhibit tumor growth in patient-derived ex vivo and in vivo models by modulating signaling, cell stemness and the tumor immune microenvironment. Given the differentiated mechanism of action, the identification of Claudin-1 as a novel therapeutic target for HCC provides an opportunity to break the plateau of limited treatment response. The results of this preclinical study pave the way for the clinical development of Claudin-1-specific antibodies for the treatment of advanced HCC. It is therefore of key impact for physicians, scientists and drug developers in the field of liver cancer and gastrointestinal oncology." @default.
• W4307657319 created "2022-11-04" @default.
• W4307657319 creator A5000691119 @default.
• W4307657319 creator A5001718749 @default.
• W4307657319 creator A5002435284 @default.
• W4307657319 creator A5007585092 @default.
• W4307657319 creator A5007607351 @default.
• W4307657319 creator A5012317164 @default.
• W4307657319 creator A5013323616 @default.
• W4307657319 creator A5015187303 @default.
• W4307657319 creator A5018287540 @default.
• W4307657319 creator A5021030153 @default.
• W4307657319 creator A5021072349 @default.
• W4307657319 creator A5022155277 @default.
• W4307657319 creator A5027205297 @default.
• W4307657319 creator A5027338121 @default.
• W4307657319 creator A5031939924 @default.
• W4307657319 creator A5037577234 @default.
• W4307657319 creator A5038993090 @default.
• W4307657319 creator A5039018973 @default.
• W4307657319 creator A5045580438 @default.
• W4307657319 creator A5047086660 @default.
• W4307657319 creator A5047104273 @default.
• W4307657319 creator A5047475639 @default.
• W4307657319 creator A5049436275 @default.
• W4307657319 creator A5058914166 @default.
• W4307657319 creator A5059770555 @default.
• W4307657319 creator A5059847514 @default.
• W4307657319 creator A5063547376 @default.
• W4307657319 creator A5063805890 @default.
• W4307657319 creator A5064406116 @default.
• W4307657319 creator A5064926938 @default.
• W4307657319 creator A5065507726 @default.
• W4307657319 creator A5069434079 @default.
• W4307657319 creator A5070971840 @default.
• W4307657319 creator A5074584671 @default.
• W4307657319 creator A5076915854 @default.
• W4307657319 creator A5077030202 @default.
• W4307657319 creator A5077171473 @default.
• W4307657319 creator A5078392135 @default.
• W4307657319 creator A5078443550 @default.
• W4307657319 creator A5080651597 @default.
• W4307657319 creator A5083166178 @default.
• W4307657319 creator A5085978556 @default.
• W4307657319 date "2023-02-01" @default.
• W4307657319 modified "2023-09-24" @default.
• W4307657319 title "Treatment of HCC with claudin-1-specific antibodies suppresses carcinogenic signaling and reprograms the tumor microenvironment" @default.
• W4307657319 cites W1966731849 @default.
• W4307657319 cites W2012034410 @default.
• W4307657319 cites W2023815439 @default.
• W4307657319 cites W2025599128 @default.
• W4307657319 cites W2097259163 @default.
• W4307657319 cites W2144463869 @default.
• W4307657319 cites W2159662576 @default.
• W4307657319 cites W2747830013 @default.
• W4307657319 cites W2805685454 @default.
• W4307657319 cites W2885162827 @default.
• W4307657319 cites W2932470287 @default.
• W4307657319 cites W2952676090 @default.
• W4307657319 cites W3025022288 @default.
• W4307657319 cites W3029777522 @default.
• W4307657319 cites W3092048236 @default.
• W4307657319 cites W3092251629 @default.
• W4307657319 cites W3162215872 @default.
• W4307657319 cites W3212903603 @default.
• W4307657319 cites W4210774372 @default.
• W4307657319 doi "https://doi.org/10.1016/j.jhep.2022.10.011" @default.
• W4307657319 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36309131" @default.
• W4307657319 hasPublicationYear "2023" @default.
• W4307657319 type Work @default.
• W4307657319 citedByCount "3" @default.
• W4307657319 countsByYear W43076573192023 @default.
• W4307657319 crossrefType "journal-article" @default.
• W4307657319 hasAuthorship W4307657319A5000691119 @default.
• W4307657319 hasAuthorship W4307657319A5001718749 @default.
• W4307657319 hasAuthorship W4307657319A5002435284 @default.
• W4307657319 hasAuthorship W4307657319A5007585092 @default.
• W4307657319 hasAuthorship W4307657319A5007607351 @default.
• W4307657319 hasAuthorship W4307657319A5012317164 @default.
• W4307657319 hasAuthorship W4307657319A5013323616 @default.
• W4307657319 hasAuthorship W4307657319A5015187303 @default.
• W4307657319 hasAuthorship W4307657319A5018287540 @default.
• W4307657319 hasAuthorship W4307657319A5021030153 @default.
• W4307657319 hasAuthorship W4307657319A5021072349 @default.
• W4307657319 hasAuthorship W4307657319A5022155277 @default.
• W4307657319 hasAuthorship W4307657319A5027205297 @default.
• W4307657319 hasAuthorship W4307657319A5027338121 @default.
• W4307657319 hasAuthorship W4307657319A5031939924 @default.
• W4307657319 hasAuthorship W4307657319A5037577234 @default.
• W4307657319 hasAuthorship W4307657319A5038993090 @default.
• W4307657319 hasAuthorship W4307657319A5039018973 @default.
• W4307657319 hasAuthorship W4307657319A5045580438 @default.
• W4307657319 hasAuthorship W4307657319A5047086660 @default.
• W4307657319 hasAuthorship W4307657319A5047104273 @default.
• W4307657319 hasAuthorship W4307657319A5047475639 @default.
• W4307657319 hasAuthorship W4307657319A5049436275 @default.
• W4307657319 hasAuthorship W4307657319A5058914166 @default.
• W4307657319 hasAuthorship W4307657319A5059770555 @default.

• next